AUTHORS
Chong Wei, MD, Danqing Zhao2, Yan Zhang, MD3, Jian Li, MD4, Wei Zhang, MD5, Dao-Bin Zhou6
AFFILIATIONS
1 Peking Union Medical College Hospital, Beijing, China
2 Peking Union Medical College Hospital, Beijing, China
3 Peking Union Medical College Hospital, Beijing, China
4 Peking Union Medical College Hospital, Beijing, China
5 Peking Union Medical College Hospital, Beijing, China
6 Peking Union Medical College Hospital, Beijing, China
ABSTRACT
Background
Peripheral T-cell lymphoma (PTCL) remains an aggressive malignancy with poor outcomes after conventional CHOP-based therapy. Dysregulation of the JAK/STAT pathway is frequently observed in PTCL and represents a potential therapeutic target. Golidocitinib is an oral, selective JAK1 inhibitor with demonstrated activity in relapsed/refractory PTCL. We conducted a prospective phase I/II study to evaluate the safety and preliminary efficacy of golidocitinib combined with CHOP (Go-CHOP) as frontline therapy for PTCL.
Methods
This ongoing single-center phase I/II study enrolled patients with previously untreated PTCL according to WHO 5th edition classification. Phase I used a standard 3+3 dose-escalation design to determine the recommended phase II dose (RP2D). Patients received six cycles of CHOP every 21 days combined with golidocitinib. Responding patients could receive hematopoietic stem cell transplantation (HSCT) or golidocitinib maintenance for up to 2 years. The primary endpoints were safety, tolerability, RP2D determination, and complete remission rate (CRR). Responses were assessed according to Lugano criteria.
Results
Between August 2024 and May 2026, 42 patients were enrolled, including 6 patients in phase I and 36 patients in phase II. The median age was 55 years (range, 18–70), and 41 patients (97.6%) had stage III/IV disease. Histological subtypes included PTCL-NOS (n=20, 47.6%), nodal TFH lymphoma (n=15, 35.7%), ALCL (n=2), HSTCL (n=2), and intestinal T-cell lymphoma (n=3). No dose-limiting toxicities were observed during dose escalation, and golidocitinib 150 mg once daily was selected as the RP2D. Among 34 efficacy-evaluable patients, the overall response rate (ORR) was 82.4% (28/34), including a CRR of 64.7% (22/34). In the phase II cohort, ORR and CRR were 82.1% and 60.7%, respectively. Responses were observed across major subtypes, including PTCL-NOS (ORR 84.6%, CRR 61.5%) and nodal TFH lymphoma (ORR 71.4%, CRR 64.3%). After a median follow-up of 8 months, median progression-free survival (PFS) and overall survival (OS) were not reached. Estimated 1-year PFS and OS rates were 68.1% and 85.3%, respectively. Grade ≥3 treatment-emergent adverse events occurred in 36 patients (85.7%), most commonly neutropenia (73.8%). Febrile neutropenia occurred in 16.7% of patients. CMV reactivation occurred in 17 patients (40.5%), including 5 patients with grade 3–4 CMV end-organ disease. Exploratory genomic analysis identified JAK/STAT pathway alterations in 16 of 36 sequenced patients (44.4%). JAK/STAT pathway alterations were associated with a lower CR rate despite JAK1 inhibitor-containing therapy (adjusted OR, 0.16; 95% CI, 0.03–0.95; P=0.043), suggesting heterogeneous dependence on JAK1 signaling.
Conclusion
Frontline Go-CHOP demonstrated encouraging preliminary efficacy with a high CR rate in previously untreated PTCL. CMV reactivation represents an important safety consideration requiring proactive monitoring and optimized supportive strategies. These findings support further evaluation of JAK1 inhibition combined with chemotherapy in PTCL, including randomized studies.
DISCLOSURES
Chong Wei, MD: No relevant conflicts of interest to declare.